Brief Summary
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of GSK4381562 in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.
Intervention / Treatment
- Drug: GSK4381562
- Drug: Dostarlimab
- Drug: Belrestotug
- Drug: Nelistotug
- Drug: GSK5764227
Inclusion criteria:
- A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:
- Is not a woman of childbearing potential (WOCBP) or
- Is a WOCBP and using a contraceptive method that is highly effective with a failure rate of less than (<)1 percent ([%] per year), during the intervention period and for specified time after end of study treatment.
- A WOCBP must have a negative highly sensitive pregnancy test within 24-48 hours before the first dosethe amount of medication taken of study intervention.
- Requirement for Arm I only: Male participants agree to use contraception and for their female partner to use contraception, if applicable.
- Histological or cytological documentation of loco-regionally recurrent solid tumors where curative treatment options have been exhausted, or metastatic solid tumors; types as follows:
- head and neck squamous cell carcinomacancer arising from tissues that line organs (HNSCC)
- non-small-cell lung cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs (NSCLC)
- breast cancer (BC)
- clear cell renal cell cancer (ccRCC)
- gastric cancer (GC)
- colorectalrelating to the colon or rectum in the large bowel/intestine cancer (CRC)
- endometrial cancer (EC)
- epithelial ovarian, fallopian tube, and primary peritoneal cancers- Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists.
- Measurable disease per RECIST 1.1.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status (PS) 0-1.
- Life expectancy of at least 12 weeks.
- Adequate organ function, as defined in the protocol.
- For participants enrolled in a PK/PD cohort, participant agrees to a fresh tumor biopsyremoval of a section of tissue to analyse for cancer cells during Screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening and at approximately 6-weeks after treatment initiation.